Adjuvantation of epidermal powder immunization

Vaccine

Volumn 19, Issue 20-22, 2001, Pages 2908-2917

  Chen, Dexiang ^a   Erickson, Cherie A ^a   Endres, Ryan L ^a   Periwal, Sangeeta B ^a   Chu, Qili ^a   Shu, Cassandra ^b   Maa, Yuh Fun ^b   Payne, Lendon G ^a  

^a PowderJect Vaccines Inc   (United States)

^b Powderject Technologies Inc   (United States)

Author keywords

Adjuvant; Epidermis; Vaccine

Indexed keywords

ALUMINUM PHOSPHATE; DIPHTHERIA TOXIN; DIPHTHERIA VACCINE; NEUTRALIZING ANTIBODY; OLIGONUCLEOTIDE; SYNTHETIC PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CORYNEBACTERIUM; DIPHTHERIA; DRUG POTENCY; EPIDERMIS; FEMALE; HUMORAL IMMUNITY; INJECTION; MOUSE; NEEDLE; NONHUMAN; POWDER; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, BACTERIAL; CERCOPITHECUS AETHIOPS; CYTOKINES; DINUCLEOSIDE PHOSPHATES; DIPHTHERIA TOXOID; FEMALE; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; POWDERS; T-LYMPHOCYTES; VACCINES; VERO CELLS;

EID: 0035815553     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00544-2     Document Type: Article

References (43)

1. Recommended childhood immunization schedule - United States
2. Does a needleless injection system reduce anxiety in children receiving intramuscular injections?
3. Infection prevention and control in the era of the AIDS/HIV epidemic
4. Protecting patients and professional from blood-borne disease
5. Bacterial toxins as mucosal adjuvants
6. Skin immunization made possible by cholera toxin
7. Future vaccines and a global perspective
8. Development of oral vaccines to stimulate mucosal and systemic immunity: Barriers and novel strategies
9. Preexposure immunization with intradermal human diploid cell rabies vaccine. Risk and benefits of primary and booster vaccination
10. Efficacy of hepatitis B immunization with reduced intradermal doses
11. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations
12. Transdermal immunization with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes
13. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
14. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
15. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
16. Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice
17. Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoids
18. Micro cell culture for determination of diphtheria toxin and antitoxin using VERO cells. I. Studies in factors affecting the toxin and antitoxin titration
19. Micro cell culture for determination of diphtheria toxin and antitoxin using VERO cells. II. Comparison with the rabbit skin method and practical application for sero-epidemiological studies
20. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes
21. Comparison of adjuvant activities of aluminum phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid
22. Adjuvants for human vaccines - Current status, problems and future prospects
23. The selective induction of different immune responses by vaccine adjuvants
24. Adjuvants in perspective
25. The polyclonal and antigen-specific IgE and IgG subclass response of mice injected with ovalbumin in aluminum or complete Freund's adjuvant
26. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
27. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
28. CpG DNA a novel immune enhancer for systemic and mucosal immunization with influenza virus
29. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
30. Activation of cutaneous dendritic cells by CpG DNA-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA
31. Bacterial DNA and immunostimulatory CpG DNA oligonucleotides trigger maturation and activation of murine dendritic cells
32. HIV-peplotion vaccine. A novel approach to vaccination against AIDS by transepithelial transport of viral peptides to Langerhans cells for induction of cytolytic T cells by HLA class I and CD1 molecules for long term protection
33. DNA-based immunization by in vivo transfection of dendritic cells
34. Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major
35. Adjuvant properties of aluminum and calcium compounds
36. CpG DNA oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
37. CpG DNA DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
38. IFN-gamma promotes IL-6 and IgM secretion in response to CpG DNA motifs in bacterial DNA and oligodeoxynucleotides
39. CpG DNA oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis
40. Adjuvants - A classification and review of their modes of action
41. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents